PLASMA PROTEIN THERAPEUTICS ASSOCIATION

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$12.1M

Filings

204

Firms Hired

Active Period

2001–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$740,000	8	2
2025	$580,000	9	2
2024	$605,000	8	2
2023	$530,000	8	2
2022	$640,000	8	2
2021	$630,000	8	2
2020	$620,000	8	2
2019	$630,000	8	2
2018	$660,000	8	2
2017	$750,000	11	2
2016	$750,000	14	3
2015	$367,057	11	2
2014	$353,873	13	4
2013	$557,918	9	3
2012	$710,825	11	2
2011	$1,705,250	14	2
2010	$520,000	11	3
2009	$520,000	12	3
2008	$260,000	11	3
2007	—	6	2
2006	—	4	2
2005	—	2	1
2001	—	2	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
PLASMA PROTEIN THERAPEUTICS ASSOCIATION	$12,129,923	98
WILLIAMS AND JENSEN, PLLC	—	45
KELLEY DRYE & WARREN LLP	—	29
PARRY, ROMANI, DECONCINI & SYMMS	—	14
BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ	—	8
PODESTA GROUP, INC.	—	3
DLA PIPER LLP (US)	—	4
HOGAN LOVELLS US LLP	—	3

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	191
SENATE	190
Centers For Medicare and Medicaid Services (CMS)	94
Health Resources & Services Administration (HRSA)	45
Health & Human Services, Dept of (HHS)	42
Commerce, Dept of (DOC)	30
Homeland Security, Dept of (DHS)	30
State, Dept of (DOS)	30
Centers For Disease Control & Prevention (CDC)	27
Food & Drug Administration (FDA)	22
U.S. Trade Representative (USTR)	10
Internal Revenue Service (IRS)	7
Government Accountability Office (GAO)	5
Executive Office of the President (EOP)	2
Office of Management & Budget (OMB)	2
Defense, Dept of (DOD)	1
Treasury, Dept of	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	176
Medicare/Medicaid	Medicare/Medicaid	151
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	63
Trade (domestic/foreign)	Trade (domestic/foreign)	15
Budget/Appropriations	Budget/Appropriations	11
Pharmacy	Pharmacy	5
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2026 · third_quarter · Firm: WILLIAMS AND JENSEN, PLLC

Open original LDA filing ↗

Cited source text and reported amounts

Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2026 · second_quarter · Firm: WILLIAMS AND JENSEN, PLLC

Open original LDA filing ↗

Cited source text and reported amounts

Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1

H.R. 3808119th Congress

Expanding Seniors Access to Mental Health Services Act

2026 · first_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.

Client expense: $160,000 · Firm income: —

Matched citations: HR 3808

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2026 · first_quarter · Firm: WILLIAMS AND JENSEN, PLLC

Open original LDA filing ↗

Cited source text and reported amounts

Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1

Show 21 more cited filings

H.R. 3808119th Congress

Expanding Seniors Access to Mental Health Services Act

2026 · first_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.

Client expense: $100,000 · Firm income: —

Matched citations: HR 3808

H.R. 3808119th Congress

Expanding Seniors Access to Mental Health Services Act

2025 · fourth_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.

Client expense: $100,000 · Firm income: —

Matched citations: HR 3808

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2025 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC

Open original LDA filing ↗

Cited source text and reported amounts

Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1

H.R. 3808119th Congress

Expanding Seniors Access to Mental Health Services Act

2025 · fourth_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.

Client expense: $100,000 · Firm income: —

Matched citations: HR 3808

H.R. 6465118th Congress

PLASMA Act

2025 · third_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Medicare Part B provisions relating to home infusion of IVIG. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.

Client expense: $100,000 · Firm income: —

Matched citations: HR 6465

H.R. 3808119th Congress

Expanding Seniors Access to Mental Health Services Act

2025 · third_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.

Client expense: $100,000 · Firm income: —

Matched citations: HR 3808

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2025 · third_quarter · Firm: WILLIAMS AND JENSEN, PLLC

Open original LDA filing ↗

Cited source text and reported amounts

Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1

H.R. 6465118th Congress

PLASMA Act

2025 · second_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Medicare Part B provisions relating to home infusion of IVIG. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.

Client expense: $125,000 · Firm income: —

Matched citations: HR 6465

H.R. 3808119th Congress

Expanding Seniors Access to Mental Health Services Act

2025 · second_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.

Client expense: $125,000 · Firm income: —

Matched citations: HR 3808

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2025 · second_quarter · Firm: WILLIAMS AND JENSEN, PLLC

Open original LDA filing ↗

Cited source text and reported amounts

Matters related to access to and pricing of plasma derived products and matters affecting the Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1

H.R. 6465118th Congress

PLASMA Act

2025 · first_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Medicare Part B provisions relating to home infusion of IVIG. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.

Client expense: $155,000 · Firm income: —

Matched citations: HR 6465

H.R. 3808119th Congress

Expanding Seniors Access to Mental Health Services Act

2025 · first_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.

Client expense: $155,000 · Firm income: —

Matched citations: HR 3808

H.R. 3808118th Congress

Afghan Allies Protection Act of 2023

2024 · fourth_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.

Client expense: $115,000 · Firm income: —

Matched citations: HR 3808

H.R. 3808118th Congress

Afghan Allies Protection Act of 2023

2024 · fourth_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.

Client expense: $115,000 · Firm income: —

Matched citations: H.R. 3808

H.R. 6465118th Congress

PLASMA Act

2024 · fourth_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.

Client expense: $115,000 · Firm income: —

Matched citations: HR 6465

H.R. 3808118th Congress

Afghan Allies Protection Act of 2023

2024 · third_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.

Client expense: $130,000 · Firm income: —

Matched citations: HR 3808

H.R. 3808118th Congress

Afghan Allies Protection Act of 2023

2024 · third_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.

Client expense: $130,000 · Firm income: —

Matched citations: H.R. 3808

H.R. 6465118th Congress

PLASMA Act

2024 · third_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.

Client expense: $130,000 · Firm income: —

Matched citations: HR 6465

H.R. 3808118th Congress

Afghan Allies Protection Act of 2023

2024 · second_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.

Client expense: $170,000 · Firm income: —

Matched citations: HR 3808

H.R. 3808118th Congress

Afghan Allies Protection Act of 2023

2024 · second_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.

Client expense: $170,000 · Firm income: —

Matched citations: H.R. 3808

H.R. 6465118th Congress

PLASMA Act

2024 · second_quarter · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Open original LDA filing ↗

Cited source text and reported amounts

Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.

Client expense: $170,000 · Firm income: —

Matched citations: HR 6465

Source: Senate LDA

PLASMA PROTEIN THERAPEUTICS ASSOCIATION — Lobbying Disclosure | Poliscope